Chris Washburn, PhD

Dr. Jean-Paul Achker said there is room for improvement of response rates with current treatment approaches. "There may be a limited window of time to maximize anti-TNFα therapy, as evidenced by the observed loss of response over time, the need to increase the dose of anti-TNFα therapy, and immunogenicity," he said.

K.V. Narayanan Menon, MD, talks about Cleveland Clinic's patients with liver cancer.

"IL-28B receptor polymorphism is an important predictor of SVR in patients treated with pegylated interferon and ribavirin," said Binu John, MD at the Cleveland Clinic.

Ahmed Kandiel, MD, MPH, kicked off the 47th Annual Gastroenterology Update with a thorough review of the current treatment landscape for moderate to severe inflammatory bowel disease, including the potential risks for side effects for each biologic agent.

Bret Lashner, MD, MPH, FACG, shares his thoughts about the first day of the 47th Annual Gastroenterology Update at the Cleveland Clinic, including the recent developments with inflammatory bowel disease and hepatitis C therapy.